dimethyl fumarate / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 27 Diseases   27 Trials   27 Trials   3795 News 


«12...1112131415161718192021...4546»
  • ||||||||||  glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
    The Patient Experience with Shared Decision Making in Multiple Sclerosis (Exhibit Hall A) -  Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_445;    
    Patients commonly switched providers because they did not feel heard. This may also play a role in the high rates of DMT switching.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Humoral and cellular immune response after SARS CoV-2 vaccine in patients with Multiple Sclerosis treated with immunosuppressant (Virtual Poster Hall) -  Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_291;    
    Eighty patients were evaluated in treatment with: 10 teriflunomide, 6 dimethyl fumarate, 13 cladribine, 8 fingolimod, 7 natalizumab, 27 ocrelizumab, 4 alemtuzumab, 5 rituximab... In our cohort the majority of immunosuppressed MS patients who are not capable of inducing an adequate humoral response, present a cellular immune response after administration of the SARS CoV-2 vaccine.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    Humoral immune response to SARS-Cov2 in treated MS patients (Exhibit Hall A) -  Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_280;    
    The adverse events on MS patients were similar to the general population. No increase of relapse activity was observed.Most of MS treated patients developed enough antibodies to SARS-CoV-2.Some patients treated with ocrelizumab , rituximab and fingolimod have no developed a humoral response to SARS-CoV-2 vaccination.Vaccination strategy in patients treated with anti-CD20 and fingolimod need further studies.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
    Rates of Multiple Sclerosis Relapse, Severe Relapse, and Health Care Resource Utilization Following COVID-19 Vaccination: Real-World Evidence from a US EMR Network (Exhibit Hall A) -  Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_272;    
    Background: Multiple sclerosis (MS) patients treated with antiCD20 therapies, including ocrelizumab (OCR) and fingolimod (FTY), show reduced response to coronavirus disease 2019 (COVID-19) vaccines, whereas response is similar between other disease modifying therapies (DMT) and untreated MS patients...Objectives: This study compared relapse (R), severe relapse (SR), and health care resource utilization (HCRU) rates between cohorts of vaccinated MS patients defined as: treated with OCR, ofatumumab, siponimod, or FTY [Cohort 1 (C1)]; treated with other DMT (C2); untreated (C3)...Majority DMT in C1 was OCR (62%) and in C2 were glatiramer acetate (30%) and dimethyl fumarate (30%)... Amongst DMT treated patients, relapses and HCRU was greatest within the OCR and FTY patient cohort.
  • ||||||||||  glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
    Multivariate Proteomic MS Disease Activity Test Result Distributions Based on Disease Modifying Therapy Categories (Exhibit Hall A) -  Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_185;    
    We find that the samples associated with the lowest disease activity scores and levels are from the anti-CD20 category, followed by the Natalizumab category. Analysis is ongoing to further evaluate distributions in patients with and without clinical or radiographic evidence of DA, to characterize disease pathway score distributions relative to the DMT category, and to evaluate the effect of time on therapy.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Journal:  Epidemiology of Pharmacological Treatment of Multiple Sclerosis in Croatia. (Pubmed Central) -  Feb 19, 2022   
    New DMTs are not as readily available in Croatia as they are in some countries. However, there is a continuous increase in the number of prescriptions, along with growing costs in pharmacological treatment of multiple sclerosis, and this can be expected to become even more pronounced in the following years, due to the abundance of new therapeutic options that are steadily becoming available.
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Preclinical Evaluation of Dimethyl Fumarate in an Aging Model of Pulmonary Fibrosis In vivo (Room 212-214 (South Building, Level 2), Moscone Center) -  Feb 19, 2022 - Abstract #ATS2022ATS_2093;    
    Here, we evaluated the pre-clinical efficacy of lung-targeted vs. systemic delivery of DMF in an aging murine model of bleomycin-induced persistent lung fibrosis... This study is the first to demonstrate the efficacy of lung-targeted DMF treatment to promote the resolution of age-dependent established lung fibrosis.Funding: Department of Veterans Affairs (LH: 1 I01 BX003919-01A1) and NIH (LH: 1R21AG054766-01)
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  LADIGAGA: Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy (clinicaltrials.gov) -  Feb 18, 2022   
    P2,  N=60, Recruiting, 
    This study is the first to demonstrate the efficacy of lung-targeted DMF treatment to promote the resolution of age-dependent established lung fibrosis.Funding: Department of Veterans Affairs (LH: 1 I01 BX003919-01A1) and NIH (LH: 1R21AG054766-01) Not yet recruiting --> Recruiting | Trial completion date: Oct 2024 --> Oct 2026 | Trial primary completion date: Oct 2022 --> Feb 2024
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Review, Journal:  Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology. (Pubmed Central) -  Feb 17, 2022   
    To date, there has been no evidence suggesting that treatment with fingolimod, dimethyl fumarate, or natalizumab leads to antibody deficiency...Immune supplementation employing Ig replacement therapy might reduce morbidity and mortality associated with SIDs in neurological conditions. In light of the broad range of existing and emerging therapies, the potential for SID warrants urgent consideration among neurologists and other healthcare professionals.
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Journal:  Dimethyl Fumarate is a Potential Therapeutic Option for Alzheimer's Disease. (Pubmed Central) -  Feb 16, 2022   
    Our findings elucidate mechanisms underlying the host response to UPEC and provide a potential strategy to combat UTIs. These results indicate that DMF is a potential therapeutic option for AD through its antioxidant, anti-inflammatory, anti-apoptotic, and other anti-AD effects by activating the Nrf2 pathway.
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Journal:  COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: What we know by May 2021. (Pubmed Central) -  Feb 16, 2022   
    We found no evidence supporting a higher prevalence of COVID-19 in pwMS compared to the general population. However, our results show pwMS to be more prone to hospitalization compared to the general population, Therefore, it is advised to use safer treatment if possible until complete vaccination, and to postpone the use of rituximab.
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Journal:  Effect of Dimethyl Fumarate (DMF) on T-cell Acute Lymphoblastic Leukemia (Pubmed Central) -  Feb 8, 2022   
    DMF inhibits the proliferation of T-cell acute lymphoblastic leukemia cell. The mechanism may be that, DMF significantly up-regulates the protein levels of Nrf2 and E3 ubiquitin ligase HACE1, and HACE1 interacts with Nrf2 and positively regulates Nrf2 protein level.
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Journal:  No Changes in Functional Connectivity After Dimethyl Fumarate Treatment in Multiple Sclerosis. (Pubmed Central) -  Feb 5, 2022   
    The absence of FC changes could be due to the low degree of baseline inflammation in our patients, though we cannot exclude that more time may be required to observe such changes. No FC changes may reflect a beneficial effect of DMF therapy, as supported by conventional MRI findings and clinical improvement.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Review, Journal:  The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review. (Pubmed Central) -  Feb 4, 2022   
    In this narrative review, we analyze pre-registration and post-marketing data concerning hepatotoxicity of all disease-modifying therapies (DMTs) available for the treatment of relapsing-remitting multiple sclerosis, including beta interferon, glatiramer acetate, fingolimod, teriflunomide, dimethyl fumarate, cladribine, natalizumab, alemtuzumab, and ocrelizumab...For some DMTs, screening for hepatitis B virus and hepatitis C virus is required before starting treatment and a monitoring or antiviral prophylaxis schedule has been established. Beta interferon, glatiramer acetate, natalizumab, and alemtuzumab are relatively contraindicated in autoimmune hepatitis due to the risk of disease exacerbation.
  • ||||||||||  Vumerity (diroximel fumarate) / Biogen
    Journal:  Diroximel Fumarate in Relapsing Forms of Multiple Sclerosis: A Profile of Its Use. (Pubmed Central) -  Feb 1, 2022   
    In RRMS patients who are treatment-naïve or were previously treated with interferon-β or glatiramer acetate, diroximel fumarate reduces annualized relapse rates, with most patients experiencing no relapses during treatment, and reduces the formation of new MS-associated brain lesions. Diroximel fumarate has an acceptable tolerability profile that is consistent with that of dimethyl fumarate, albeit with a significantly lower rate of GI adverse events.
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Clinical, Journal:  Alterations of the gut mycobiome in patients with MS. (Pubmed Central) -  Feb 1, 2022   
    There is an alteration of the gut mycobiome in pwMS, compared to healthy controls. Further study is required to assess any causal association of the mycobiome with MS and its direct or indirect interactions with bacteria and autoimmunity.
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Clinical, Journal:  Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients. (Pubmed Central) -  Jan 28, 2022   
    Furthermore, since DMF has been found to decrease immune cell migration by decreasing the expression of adhesive molecules, the cerebrospinal fluid (CSF) immune profile may also be useful for assessing PML risk in DMF-treated patients. This review provides an up-to-date assessment of PML cases occurring in DMF-treated patients and discusses other potential considerations in light of our current understanding of DMF's mechanism of action on the immune system in the periphery and in the central nervous system (CNS).
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Journal:  Drugs used in the treatment of multiple sclerosis during COVID-19 pandemic: a critical viewpoint. (Pubmed Central) -  Jan 27, 2022   
    Teriflunomide, a first-line oral drug used in the treatment of relapsing-remitting MS (RRMS), may display antiviral activity by depleting cellular nucleotides necessary for viral replication...For example, fingolimod, might be highly beneficial during the hyperinflammatory stage of COVID-19 for a number of mechanisms including the reinforcement of the endothelial barrier. Caution is suggested for the use of natalizumab, cladribine, alemtuzumab, and ocrelizumab, although MS disease recurrence after discontinuation of these drugs may overcome a potential risk for COVID-19 infection.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Clinical, Clinical data, Journal:  Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study. (Pubmed Central) -  Jan 27, 2022   
    Accordingly, in this postmenopausal AD model, DMF treatment by pursuing the adiponectin/AdipoR1, AMPK/SIRT-1, AKT/CREB/BDNF, AKT/GSK-3β, and APO-E1 quartet hampered the associated tauo-/amyloidopathy and NF-κB-mediated oxidative/inflammatory responses to advance insights into its anti-amnesic effect. Initiating MS-therapy with heDMT significantly reduced the risk of 5-year disability progression and relapse compared to using meDMT as first DMT choice in propensity-matched groups of Finnish MS-patients.
  • ||||||||||  dimethyl fumarate / Generic mfg.
    Journal:  Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment. (Pubmed Central) -  Jan 26, 2022   
    The presence of JCPyV DNA and microRNA (miR-J1-5p), the anti-JCV index and the sequence of the non-coding control region (NCCR) in urine and plasma were determined in 42 MS subjects before treatment (T0), 6 months (T6) and 12 months (T12) after natalizumab, ocrelizumab, fingolimod or dimethyl-fumarate administration and in 25 healthy controls (HC)...Viruria and miR-J1-5p expression did not correlate with anti-JCV index. In conclusion, analyzing JCPyV DNA and miR-J1-5p levels may allow monitoring JCPyV activity and predicting MS patients at risk of developing PML.